1568 related articles for article (PubMed ID: 34741251)
21. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
22. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
24. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
[TBL] [Abstract][Full Text] [Related]
25. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
[TBL] [Abstract][Full Text] [Related]
26. The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.
Serwanga J; Kato L; Oluka GK; Ankunda V; Sembera J; Baine C; Kitabye I; Namuyanja A; Opio S; Katende JS; Ejou P; ; Kaleebu P
Front Immunol; 2024; 15():1384668. PubMed ID: 38779677
[TBL] [Abstract][Full Text] [Related]
27. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.
Zeng F; Wu M; Wang J; Li J; Hu G; Wang L
J Med Virol; 2021 Dec; 93(12):6506-6511. PubMed ID: 34170519
[TBL] [Abstract][Full Text] [Related]
28. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
29. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals.
Ruggiero A; Piubelli C; Calciano L; Accordini S; Valenti MT; Carbonare LD; Siracusano G; Temperton N; Tiberti N; Longoni SS; Pizzato M; Accordini S; ; Fantoni T; Lopalco L; Beretta A; Bisoffi Z; Zipeto D
EBioMedicine; 2022 Mar; 77():103888. PubMed ID: 35196644
[TBL] [Abstract][Full Text] [Related]
31. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
32. Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients.
Movahedi M; Movahedi M; Parvaneh N; Abolhassani H; Mahdavi M; Mosavikhorshidi MS; Alizadeh F; Shokri M; Kalantari A
Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):158-167. PubMed ID: 38822511
[TBL] [Abstract][Full Text] [Related]
33. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days.
Liang XM; Xu QY; Jia ZJ; Wu MJ; Liu YY; Lin LR; Liu LL; Yang TC
Front Immunol; 2022; 13():876037. PubMed ID: 35572536
[TBL] [Abstract][Full Text] [Related]
34. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
[TBL] [Abstract][Full Text] [Related]
35. Development of a SARS-CoV-2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients.
Wang H; Li X; Li T; Wang L; Wang L; Lin J; Zhang S; Xu Y; Wei W
Clin Respir J; 2021 May; 15(5):499-505. PubMed ID: 33484220
[TBL] [Abstract][Full Text] [Related]
36. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Liu J; Huang B; Li G; Chang X; Liu Y; Chu K; Hu J; Deng Y; Zhu D; Wu J; Zhang L; Wang M; Huang W; Pan H; Tan W
J Infect Dis; 2022 May; 225(10):1701-1709. PubMed ID: 34958382
[TBL] [Abstract][Full Text] [Related]
38. Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects.
Ji R; Zhang J; Liang D; Quan H; Wu Y; Peng A; Li W; Lu S; Zhang X; Ke C; Wang D; Xu J
Viral Immunol; 2023 Nov; 36(9):593-599. PubMed ID: 37782911
[TBL] [Abstract][Full Text] [Related]
39. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
